Nordic Life Science 1
TOP STORIES ACQU I SITIONS // AGREEMENTS // COLLA
BORATIONS S TA F F R E DUC T IO N “It has not been possible to reach a common understanding following dialogue with the Novo Nordisk Foundation regarding the future composition of the Board of Directors.” Helge Lund, former Chair of the Board, Novo Nordisk C A REER S NOVO NORDISK BOARD MEMBERS LEAVE Chair Helge Lund, Vice Chair Henrik Poulsen and independent board members Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law, and Martin Mackay will not stand for election at the Extraordinary General Meeting on November 14, 2025. KASIM KUTAY (not independent) and the employee-elected board members Elisabeth Dahl Christensen, Liselotte Hyveled, Mette Bøjer Jensen, and Thomas Rantzau will remain on the Board. “It has not been possible to reach a common understanding following dialogue with the Novo Nordisk Foundation regarding the future composition of the Board of Directors. The Board proposed a renewal focusing on the addition of selected, new competencies while also maintaining continuity, whereas the Board of the Foundation wanted a more extensive reconfiguration," says Helge Lund, Chair of the Board, Novo Nordisk. After thorough deliberation and considering the Foundation’s position and control of the majority of votes in Novo Nordisk, the Board concluded that it is in the best interests of the company and its sharehol-ders to convene an Extraordinary General Meeting to elect new board members to provide clarity on the future governance of Novo Nordisk,” he adds. NLS Mendus updates clinical strategy & operational focus Mendus has announced development of vididencel as an active immunotherapy for chronic myeloid leukemia (CML) and a focus on clinical development of it. This also means organizational changes to offset new expenses. ”THE GOAL OF our clinical strategy is to further broaden the positioning of vididencel in the AML treatment landscape and in CML as a new indication. The execution of this plan requires operational focus, and we will therefore reduce our R&D activities to the level required to support our clinical programs,” says Erik Manting, CEO, Mendus. Mendus will reduce its staff from 28 to 19, including an adjustment of the company’s executive management team from 5 to 3 members. The cost savings realized by the corporate reorganization are estimated to offset the extra trial costs anticipated for 2026, states the company. NLS Erik Manting, CEO, Mendus SIX POSITIONS … … will be removed from Integrum’s current workforce as part of its organizational restructuring. 16 | NORDICLIFESCIENCE.ORG